Clinical trials: Psoriasis Patients
Arthritis, Psoriatic, Psoriasis
Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases
Despite advances in effective psoriatic disease treatment, the disease still has a serious impact on mental health and well-being of millions of patients.
- Trial name
- NCT05571696
- Testing
- Immune Strength
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Elaine Husni
Psoriasis, Moderate to Severe
Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
The purpose of this clinical research study is to learn if BMS-587101 is effective on the treatment of Moderate to Severe Psoriasis. The safety of this treatment will also be studied.
- Trial name
- NCT00162253
- Testing
- BMS 587101
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Moderate to Severe Plaque Psoriasis
Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 70 subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT05342428
- Testing
- TLL018 tablets
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Moderate to Severe Psoriasis
Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy
Adalimumab has recently been authorized for active psoriasis in Peru and local experience is very low. The aim of this study is to obtain Peruvian data of clinical effectiveness and impact on health-related quality of life with…
- Trial name
- NCT01156532
- Where
- 3 sites in Peru
- Volunteers
- 30 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Plaque Psoriasis, Biologic Agents
To Explore the Influencing Factors and Solutions for Patients With Plaque Psoriasis Undergoing Relapse
In recent years, an increasing number of patients who have experienced poor efficacy or adverse drug reactions using traditional treatment regimens have received biologic therapy and achieved satisfactory treatment results.
- Conditions
- Plaque Psoriasis, Biologic Agents, Relapse, Influence Factors
- Trial name
- NCT07730619
- Testing
- Diagnosis and Physical Examination of Psoriasis
- Where
- China
- Volunteers
- 140 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Quality of Life
Patient Centered Care Situation and Health-related Quality of Life by Patients With Psoriasis, Urticaria or Lupus
This study is based on a survey about the patient centered care situation and health-related quality of life of patients with diagnoses Psoriasis, Urtikaria or Lupus erythematodes.
- Trial name
- PUL (NCT03324919)
- Testing
- HRQL
- Where
- Germany
- Volunteers
- 220 people
- Sponsor
- University Hospital Regensburg
Psoriasis
An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients
This is a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 will be administered to normal healthy volunteers (NHV) and to moderate to severe psoriatic patients, both in sequential ascending dose…
- Trial name
- NCT02555709
- Testing
- VTP-43742
- Where
- 14 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Vitae Pharmaceuticals Inc., an Allergan affiliate
Arthritis, Psoriatic
Single Dose PG102 in Patients With Active Psoriatic Arthritis
The primary objective is to evaluate the safety and tolerability of a single intravenous dose of PG102 in patients with psoriatic arthritis.
- Trial name
- NCT00787137
- Testing
- PG102
- Where
- Serbia
- Volunteers
- 17 people
- Sponsor
- PanGenetics UK Limited
Generalized Pustular Psoriasis
An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
This Expanded Access Program in China is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP).
- Trial name
- NCT05239039
- Testing
- spesolimab
- Where
- 12 sites in China
- Volunteers
- 39 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis, Psoriatic Arthritis
Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment
The aim of this study is to examine the associations between inflammatory disease activity and endothelial function in rheumatoid arthritis (RA) and spondyloarthritis patients treated with methotrexate and Tumor Necrosis Factor…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Endothelial Dysfunction
- Trial name
- PSARA (NCT00902005)
- Where
- Norway
- Volunteers
- 145 people
- Sponsor
- Revmatismesykehuset AS
Plaque Psoriasis
A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis
The main purpose of this study is to learn more about the safety and side effects of DC-806 when given by mouth to healthy participants and participants with Chronic Plaque Psoriasis. The study will have three parts.
- Trial name
- NCT06808815
- Testing
- DC-806
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Influenza, Rheumatic Diseases
Vaccination Against Influenza H1N1 in Rheumatic Diseases
The spread of Influenza H1N1 has prompted the development of vaccines against this virus. Immunocompromised patients are at increased risk of developing complications of Influenza H1N1.
- Trial name
- NCT01006681
- Testing
- Focetria (Monovalent MF59-Adjuvanted vaccine)
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Plaque Psoriasis
A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of…
- Trial name
- NCT06380907
- Testing
- ZL-1102 1% w/w gel BID for 16 weeks, ZL-1102 3% w/w gel BID for 16 weeks, ZL-1102 3% w/w gel QD for 16 weeks
- Where
- 10 sites in Australia
- Volunteers
- 65 people
- Sponsor
- Zai Lab (Hong Kong), Ltd.
Meibomian Gland Dysfunction, Dry Eye Syndromes
Ocular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients
This observational study aims to assess the frequency and severity of Meibomian Gland Dysfunction (MGD) and associated ocular surface changes in patients with systemic autoimmune rheumatic diseases compared with healthy…
- Conditions
- Meibomian Gland Dysfunction, Dry Eye Syndromes, Rheumatoid Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT07810569
- Volunteers
- 150 people
- Sponsor
- Assiut University
Tuberculosis
A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil
This was a retrospective observational study that relied on data extracted from patient's chart review at the participating centers.
- Trial name
- ToBeReal (NCT06715254)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients
The main goal of this study is to determine optimal cut-off values of adalimumab trough levels corresponding to good clinical response.
- Trial name
- NCT02147600
- Where
- 5 sites in Belgium
- Volunteers
- 82 people
- Sponsor
- University Hospital, Ghent
Chronic Inflammatory Disease
Chronic Inflammatory Rheumatism: Management of Comorbidities in Ambulatory Medicine
Identification of factors limiting compliance with the recommendations established during the evaluation of the SCORIC population by the rheumatology department of the CHU Grenoble Alpes
- Trial name
- SCORIC-A (NCT05613712)
- Testing
- Patients, Referring physician
- Where
- France
- Volunteers
- 229 people
- Sponsor
- University Hospital, Grenoble
Psoriasis, Plaque
A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis
The purpose of this study is to assess the severity of plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches.
- Trial name
- NCT02274363
- Testing
- No Intervention
- Where
- 16 sites in Brazil
- Volunteers
- 1,131 people
- Sponsor
- Janssen Pharmaceutica
Psoriasis
Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life
This observational study will document to what extent in daily clinical practice Humira (adalimumab) therapy is continued, interrupted or permanently discontinued during a follow-up period of 2 years.
- Trial name
- NCT01169987
- Volunteers
- 191 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.